Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences QbD in Pharma Development World Congress 2017

Sushil Srivastava's Biography



Sushil Srivastava, Process Research and Development Director, Bristol-Myers Squibb

Dr. Sushil K. Srivastava is the Director of Chemical Development (Drug Substance), Pharmaceutical Development at Bristol-Myers Squibb (BMS). He is responsible for late phase development including QbD/PAT, technology transfer of drug substance processes to commercial manufacturing sites and providing source documents for CMC filings and responses to Health Authority questions. He received his Ph.D. degree in synthetic organic chemistry from Banaras Hindu University, Varanasi, India in 1978 and had post doctoral experience in physical organic chemistry with Prof. W. J. le Noble, State University of New York, Stony Brook, NY and E. C. Ashby, Georgia Tech at Atlanta, GA prior to joining BMS in 1987.

Sushil Srivastava Image

QbD in API Manufacturing Process: Strategy for Successful timely Regulatory Approval using QbD

Thursday, 20 April 2017 at 14:00

Add to Calendar ▼2017-04-20 14:00:002017-04-20 15:00:00Europe/LondonQbD in API Manufacturing Process: Strategy for Successful timely Regulatory Approval using QbDQbD in Pharma Development World Congress 2017 in HyderabadHyderabadSELECTBIOenquiries@selectbiosciences.com


Add to Calendar ▼2017-04-20 00:00:002017-04-21 00:00:00Europe/LondonQbD in Pharma Development World Congress 2017QbD in Pharma Development World Congress 2017 in HyderabadHyderabadSELECTBIOenquiries@selectbiosciences.com